ATE507240T1 - Materialien und verfahren für wachstumsfaktorbindende konstrukte - Google Patents

Materialien und verfahren für wachstumsfaktorbindende konstrukte

Info

Publication number
ATE507240T1
ATE507240T1 AT05725099T AT05725099T ATE507240T1 AT E507240 T1 ATE507240 T1 AT E507240T1 AT 05725099 T AT05725099 T AT 05725099T AT 05725099 T AT05725099 T AT 05725099T AT E507240 T1 ATE507240 T1 AT E507240T1
Authority
AT
Austria
Prior art keywords
growth factor
methods
materials
binding constructs
factor binding
Prior art date
Application number
AT05725099T
Other languages
English (en)
Inventor
Kari Alitalo
Markku M Jeltsch
Original Assignee
Vegenics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vegenics Pty Ltd filed Critical Vegenics Pty Ltd
Application granted granted Critical
Publication of ATE507240T1 publication Critical patent/ATE507240T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ceramic Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05725099T 2004-03-05 2005-03-07 Materialien und verfahren für wachstumsfaktorbindende konstrukte ATE507240T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55090704P 2004-03-05 2004-03-05
PCT/US2005/007741 WO2005087808A2 (en) 2004-03-05 2005-03-07 Growth factor binding constructs materials and methods

Publications (1)

Publication Number Publication Date
ATE507240T1 true ATE507240T1 (de) 2011-05-15

Family

ID=34962227

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05725099T ATE507240T1 (de) 2004-03-05 2005-03-07 Materialien und verfahren für wachstumsfaktorbindende konstrukte

Country Status (6)

Country Link
US (3) US7422741B2 (de)
EP (1) EP1732947B1 (de)
AT (1) ATE507240T1 (de)
AU (1) AU2005222384A1 (de)
DE (1) DE602005027673D1 (de)
WO (1) WO2005087808A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US20060110364A1 (en) * 2004-08-20 2006-05-25 Ludwig Institute For Cancer Research Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
KR101246504B1 (ko) * 2005-06-17 2013-03-26 임클론 엘엘씨 항－ＰＤＧＦＲα 항체
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
EP2125895B1 (de) * 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf-rezeptorantagonisten zur behandlung von allommunität bei organtransplantationen und atherosklerose
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
DK2215247T3 (en) * 2007-11-13 2014-12-08 Scripps Research Inst Preparation of a fusion of cytotoxic antibody toxin into eukaryotic algae
WO2009149205A2 (en) * 2008-06-03 2009-12-10 Neurotech Usa, Inc. Cell lines that secrete soluble vegf receptors and uses thereof
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CN103533950A (zh) 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
CA2862270A1 (en) * 2011-12-29 2013-07-04 Baylor Research Institute Biomarkers of kawasaki disease
EP2911681A1 (de) 2012-10-26 2015-09-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Lyve-1-antagonisten zur vorbeugung oder behandlung eines pathologischen leidens in zusammenhang mit lymphangiogenese
CN103113468B (zh) * 2013-01-17 2014-05-21 中国人民解放军军事医学科学院基础医学研究所 一种抗肿瘤蛋白质
MY199344A (en) * 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
US8895611B1 (en) 2013-07-17 2014-11-25 King Fahd University Of Petroleum And Minerals Cytotoxic compounds for treating cancer
KR102060187B1 (ko) * 2013-07-19 2019-12-27 삼성전자주식회사 Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
KR102213653B1 (ko) * 2014-02-21 2021-02-09 베지닉스 피티와이 리미티드 리간드 결합 분자 및 이의 용도
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MX379491B (es) * 2014-06-28 2025-03-10 Kodiak Sciences Inc Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf)
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
AU2016413999B2 (en) * 2016-07-05 2020-05-14 Ibentrus, Inc. Cancer treatment composition for inhibiting tumor angiogenesis, containing VEGF deep blocker, and preparation method therefor
KR20190050807A (ko) 2016-09-09 2019-05-13 메르크 파텐트 게엠베하 고체 약학적 투여 형태의 제조 방법
AU2018375398C1 (en) 2017-11-30 2026-01-15 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
MX2023004839A (es) * 2020-10-30 2023-06-29 Eluminex Biosciences Suzhou Ltd Inhibidores de factores angiogenicos.

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5474982A (en) 1986-08-13 1995-12-12 Zymogenetics, Inc. PDGF analogs and methods of use
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DK0418099T3 (da) 1989-09-15 2002-04-02 Res Triangle Inst Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
GB9101645D0 (en) 1991-01-25 1991-03-06 British Bio Technology Compounds
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
PT733103E (pt) 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
FR2716682B1 (fr) 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US5686278A (en) 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US5773289A (en) 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US5830727A (en) 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
ZA9711456B (en) 1996-12-20 1998-06-30 Ludwig Inst Cancer Res VEGF-B/receptor complex and uses thereof.
WO1998031794A1 (fr) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
US20020164687A1 (en) 1998-09-30 2002-11-07 Ulf Eriksson Platelet-derived growth factor C, DNA coding therefor, and uses thereof
EP1126871A2 (de) 1998-10-16 2001-08-29 The Government of The United States of America, as represented by The Department of Health and Human Services Kombinationstherapie mit vip antagonisten
FR2785044B1 (fr) 1998-10-27 2001-01-26 Gemplus Card Int Gabarit universel de controle geometrique d'une carte
US7148037B2 (en) 1998-11-10 2006-12-12 Ludwig Institute For Cancer Research Platelet-derived growth factor D, DNA coding therefor, and uses thereof
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AU2001239884B2 (en) 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
HUP0302779A3 (en) 2000-06-23 2005-12-28 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
WO2002022176A1 (en) 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
US6464820B2 (en) * 2000-12-29 2002-10-15 Basf Corporation Binder resin and synergist composition including a parting agent and process of making lignocellulosic
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) * 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
TWI320038B (en) * 2001-03-30 2010-02-01 An 1,4-dihydropiridine derivatives pharmacologically with adrenoceptor and calcium channel blocking activities
WO2003020906A2 (en) 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도

Also Published As

Publication number Publication date
AU2005222384A1 (en) 2005-09-22
US20110243912A1 (en) 2011-10-06
US20090155268A1 (en) 2009-06-18
WO2005087808A2 (en) 2005-09-22
EP1732947A2 (de) 2006-12-20
US7855178B2 (en) 2010-12-21
US7422741B2 (en) 2008-09-09
EP1732947B1 (de) 2011-04-27
DE602005027673D1 (de) 2011-06-09
WO2005087808A3 (en) 2005-12-01
US20060030000A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
DE602005027673D1 (de) Materialien und verfahren für wachstumsfaktorbindende konstrukte
EA200801521A1 (ru) Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
DE60131146D1 (de) Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
EP2331136A4 (de) Frizzled-bindende stoffe und ihre verwendungen
EP2052746A3 (de) Verfahren zum Herstellen eines hämostatischen Wundverbands
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EP2366716A3 (de) Kombinationstherapie mit Alpha5beta1-Antagonisten
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
EA201290525A1 (ru) Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения
PH12013502205A1 (en) Antibodies to il-6 and their uses
UA92154C2 (ru) Rage-слитые белки и способы их применения
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2011038301A3 (en) Screening methods
EP3248617A3 (de) Antikörper gegen erbb3 und verwendungen davon
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
ATE461220T1 (de) Anti-egfr-antikörper
UA93356C2 (ru) Белки слияния ha ochobe rage и способы их использования
TW200700081A (en) Anti-ctla-4 antibody compositions
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
EP2579895A4 (de) Anti-vegf-antikörper und verwendungen davon
WO2007092932A3 (en) Bivalent erbb ligand binding molecules and methods for their preparation and use
EP3483267A3 (de) Integrin-alpha 8-beta-1-spezifischer monoklonaler antikörper
WO2005016963A3 (en) Heparin binding veger-3 ligands
WO2006138670A3 (en) Antibody complexes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties